SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- December 11, 2006 -- Novacea, Inc. (NASDAQ: NOVC) today announced that Phase 1 data of AQ4N (banoxantrone), an investigational anti-cancer prodrug, demonstrated that AQ4N was active and well tolerated when administered to patients with non-Hodgkin's, chronic lymphocytic and Hodgkin's lymphomas. Results from the Phase 1, open-label, dose-escalation study at Weill Medical College of Cornell University, Washington University School of Medicine, and The Johns Hopkins University, were presented by investigators at the American Society of Hematology (ASH) 48th Annual Meeting on Sunday, December 10, 2007.
